Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Posted on by Pencis

Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Chongqing Medical University | China

Author Profile

Scopus

ORCID ID

Professor Yinyuan Ding

🌟 Professor of Oncology
🏥 Chongqing Medical University

🎓 Academic and Professional Background:

Professor Yinyuan Ding obtained a Ph.D. from Peking University in 2011 and pursued postdoctoral training at UT Southwestern Medical Center, where he was later promoted to Assistant Professor in 2018. In 2019, he returned to China and joined Chongqing Medical University as a professor. His research explores tumorigenesis and glucolipid metabolic disorders, focusing on the LRP1 receptor’s role in liver and vascular signaling, with implications for novel treatments for Hepatocellular Carcinoma (HCC) and Metabolic Associated Steatohepatitis-Liver Disease (MASLD).

🔬 Research and Innovations:

  • Principal Investigator
    2023-2026: “The role of LRP1 in hepatic glucose metabolism and HCC progression” (National Natural Science Foundation of China)
    2021: “The role of Asprosin in hepatocellular carcinoma” (Chongqing Municipal Human Resources Bureau)

 

  • Participant
    2015-2020: “VLDL and ApoE receptors metabolism” (NIH-NHLBI)
    2011-2015: “Cell signaling and cholesterol-lipoprotein receptors” (NIH)

📚 Journals Published:

Advanced Science, Elife, Science Signaling, EBioMedicine, JBC

🤝 Collaborations:

Collaborates with Joachim Herz (UT Southwestern Medical Center, USA)

👥 Professional Memberships:

Director of the China Branch, International Atherosclerosis Society

🧬 Areas of Research:

  • Oncology
  • Tumorigenesis
  • Hepatology
  • Lipoprotein & Lipid Research

📝 Contributions:

Professor Ding’s groundbreaking research on LRP1 has revealed its multifaceted roles in regulating cholesterol and glucose metabolism. His work identified a critical mechanism by which LRP1 affects hepatic insulin resistance, dyslipidemia, and HCC progression. This novel insight into LRP1’s function opens pathways for innovative therapeutic strategies for cancer and metabolic disorders.

✨Conclusion:

In summary, Professor Yinyuan Ding is a distinguished expert in oncology and hepatology, with a strong focus on the molecular mechanisms of tumorigenesis and lipid metabolism disorders. His innovative research on LRP1 has led to significant breakthroughs in understanding liver disease and cancer progression, paving the way for novel therapeutic strategies. With a wealth of experience from top institutions and numerous prestigious publications and patents, Professor Ding continues to make impactful contributions to the field of cancer research, driving advancements in both basic science and clinical applications. 🌟

📊🔬NOTABLE PUBLICATION:

1. LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice

  • Authors: Guo, X., Pu, J., Tang, Z., Liu, T., Ding, Y.
  • Journal: Animal Models and Experimental Medicine
  • Year: 2024

2. Erratum: Correction: LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis

  • Authors: Xian, X., Ding, Y., Dieckmann, M., Tsai, S., Herz, J.
  • Journal: eLife
  • Year: 2017 (Erratum published in 2024)

3. Loss of LRP1 Promotes Hepatocellular Carcinoma Progression via UFL1-Mediated Activation of NF-κB Signaling

  • Authors: Guo, X., Yang, F., Liu, T., Herz, J., Ding, Y.
  • Journal: Advanced Science
  • Year: 2024

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

🌟 Distinguished Scientist Award: Dr. Chen Wang 🌟

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

📚 Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

🧬 Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

🏆 Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

🌐 Professional Links

📄 Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

📊🔬Notable Publication: